Overview

Phase II Efficacy Study of AZD6244 in Colorectal Cancer

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess if there is benefit when using AZD6244 in the treatment if metastatic colorectal cancer in comparison with another treatment called capecitabine. This study will also assess how safe and well tolerated AZD6244 is.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Capecitabine